Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge

2026-02-11 08:50:49 ET

Thesis

Evommune ( EVMN ) stock has done extremely well this week due to some very positive data from their EVO301 Phase 2a study. The study focused on moderate-to-severe atopic dermatitis ( AD ) and showed very rapid and statistically significant reductions in EASI scores at weeks 4, 8, and 12. There was also a 33% placebo-adjusted improvement, with 23% of patients achieving vIGA-AD 0/1 by week 12. On the day of the announcement, the stock surged roughly 70% simply due to how promising the results were. What made the market even more bullish is that EVO301 may also have potential in other therapeutic areas since it targets more than one immune axis. The company is also going through with a Phase 2b dose-selecting study, but this time with a subcutaneous formulation....

Read the full article on Seeking Alpha

For further details see: